Combination of Ceralasertib and Olaparib in Acquired PARP-Inhibitor-Resistant HR Deficient Ovarian Cancer
16598
post-template-default,single,single-post,postid-16598,single-format-standard,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-5.7,vc_responsive
 

Combination of Ceralasertib and Olaparib in Acquired PARP-Inhibitor-Resistant HR Deficient Ovarian Cancer

Home > Blogs  > Combination of Ceralasertib and Olaparib in Acquired PARP-Inhibitor-Resistant HR Deficient Ovarian Cancer

07 Sep Combination of Ceralasertib and Olaparib in Acquired PARP-Inhibitor-Resistant HR Deficient Ovarian Cancer

Posted at 09:24h in Blogs by

In the phase 2 CAPRI  trial, patients with recurrent, platinum-sensitive BRCA1/2 mutated or homologous recombination (HR) deficient high-grade serous ovarian cancer (HGSOC) and clinically benefited from PARPi before progression, treated with ceralasertib (ATR inhibitor) and olaparib (PARP inhibitor) showed ORR of 50% (95% confidence interval, 0.15-0.72). ATR inhibition re-sensitizes PARPi-resistant cells to PARP inhibition and has an apparent synergistic effect with PARP inhibition. Grade 3/4 toxicities were 38%: anemia (15%), thrombocytopenia (23%), and neutropenia (8%). The combination was tolerable and showed activity in patients who progressed with PARPi as the penultimate regimen. (Ref: Wethington SL, et al. Clin Cancer Res. August 1, 2023)

#oncologyresearch #clinicalresearch #clinicaldevelopment

No Comments

Sorry, the comment form is closed at this time.